Health Care · NYSE: DOCS
Doximity earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends March · next results expected around 4 Feb 2027
Latest: Q2 FY2027
Doximity paired its new DoseCheck medication-safety verifier with UpToDate content in its clinical AI as more than 190 health systems bought the AI suite and pharma began buying AI search.
Doximity launched DoseCheck, a deterministic verifier that checks AI drug-dose answers against its own drug dataset, and added UpToDate to its AI answers. More than 190 health systems now buy its AI suite, including New York Presbyterian, which offers it inside its electronic health record. A new patient context feature lets doctors ask chart-specific questions. On the pharma side, 16 of the top 20 companies have bought AI search, a product that places advertising inside AI answers.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q3 FY25 | $168.6M |
| Q4 FY25 | $138.3M * |
| Q1 FY26 | $145.9M |
| Q2 FY26 | $168.5M |
| Q3 FY26 | $185.1M |
| Q4 FY26 | $145.4M * |
| Q1 FY27 | $156.6M |
| Q2 FY27 | $174.5M |
Data
| Q3 FY25 | $0.37 |
| Q1 FY26 | $0.27 |
| Q2 FY26 | $0.31 |
| Q3 FY26 | $0.31 |
| Q1 FY27 | $0.13 |
| Q2 FY27 | $0.18 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q3 FY25 | 47.4% |
| Q4 FY25 | 35.2% |
| Q1 FY26 | 37.4% |
| Q2 FY26 | 37.8% |
| Q3 FY26 | 38.9% |
| Q4 FY26 | 17.1% |
| Q1 FY27 | 21.5% |
| Q2 FY27 | 25.2% |
Data
| Q3 FY25 | $65.2M |
| Q4 FY25 | $98.5M |
| Q1 FY26 | $62.1M |
| Q2 FY26 | $93.9M |
| Q1 FY27 | $41.9M |
| Q2 FY27 | $93.3M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $168.6M | $138.3Md | $145.9M | $168.5M | $185.1M | $145.4Md | $156.6M | $174.5M |
| Gross margin | 91.6% | 89.5% | 89.2% | 90.3% | 89.9% | 86.7% | 84.9% | 85.5% |
| Operating income | $79.9M | $48.7Md | $54.5M | $63.7M | $71.9M | $24.8Md | $33.6M | $43.9M |
| Operating margin | 47.4% | 35.2% | 37.4% | 37.8% | 38.9% | 17.1% | 21.5% | 25.2% |
| Net income | $75.2M | $62.5Md | $53.3M | $62.1M | $61.6M | $19.1Md | $24.3M | $34.7M |
| Diluted EPS | $0.37 | — | $0.27 | $0.31 | $0.31 | — | $0.13 | $0.18 |
| Operating cash flow | $65.2Md | $98.5Md | $62.1M | $93.9Md | $60.9Md | $109.5Md | $42.0M | $93.3Md |
| Capital expenditure | $0.00d | $0.00d | $0.00 | $0.00d | — | — | $62.0K | $0.00d |
| Free cash flow | $65.2M | $98.5M | $62.1M | $93.9M | — | — | $41.9M | $93.3M |
| R&D expense | $22.4M | $24.8Md | $26.8M | $30.2M | $34.6M | $39.1Md | $38.5M | $42.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 5 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 6 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 19 May 202610-K for the period ended 31 Mar 2026SEC ↗
- 5 Feb 202610-Q for the period ended 31 Dec 2025SEC ↗
- 6 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 7 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 20 May 202510-K for the period ended 31 Mar 2025SEC ↗
- 6 Feb 202510-Q for the period ended 31 Dec 2024SEC ↗